logo
Norovirus Outbreaks Surge on Cruise Ships—Here's How the CDC Says Passengers Should Protect Themselves

Norovirus Outbreaks Surge on Cruise Ships—Here's How the CDC Says Passengers Should Protect Themselves

Yahoo01-05-2025

Thus far in 2025, the CDC has issued notifications on 16 separate cruise outbreaks, outpacing the yearly totals from 2024 and 2023. That's not to say travelers should not go on cruises, but they should stay aware of the best practices. Here's what the CDC advises.Cruise ship passengers should be aware of a heightened risk of illness on their vessels, according to the Centers for Disease Control and Prevention (CDC).
There have been 16 separate outbreaks of gastrointestinal illness on board cruise ships that met the CDC's criteria for public notification thus far in 2025. Of the 13 outbreak, 10 were norovirus. Some 150 passengers crew members fell ill with norovirus during the most recent reported outbreak aboard Holland America Line's Eurodam.
'In the 2024-2025 season, a new strain of norovirus (GII.17) became predominant,' a CDC spokesperson told Travel + Leisure. 'In years when there is a new strain of the virus, there can be increased norovirus illness.'
Compared to previous years, that number is already high: 2024 saw 18 outbreaks total, while 2023 saw 14.
'Each year, there are about 2,500 reported norovirus outbreaks in the United States," the CDC spokesperson said. 'Norovirus outbreaks occur throughout the year but are most common from November to April. Most outbreaks occur when infected people spread the virus to others through direct contact (such as caring for them, sharing food, or eating utensils with them).'
Cruise ships are particularly susceptible to norovirus, due to the closed quarters that brings together many people in a new environment that can create person-to-person risks for illness to spread.
'Norovirus outbreaks can happen anywhere and can spread quickly, particularly in enclosed or crowded environments such as cruise ships. Norovirus can also persist on surfaces for extended periods and can be transmitted via food, water or viral droplets on surfaces, but the most common mode of transmission is through direct contact with infected individuals,' the CDC spokesperson told T+L.
To prevent the spread of norovirus or other gastrointestinal illnesses (referred to as AGE, or acute gastroenteritis) on cruise ships, the CDC recommends quickly reporting any illness. 'Reporting gastrointestinal illness is important. When passengers and crew tell the medical center onboard about their symptoms, it helps GI illness outbreaks get detected quickly. This allows steps to be taken to limit the spread of illness,' the CDC website states.
The CDC also advises washing your hands often (particularly before eating and after using the bathroom), and avoiding people with symptoms. "Infection control measures, such as thorough hand washing, cleaning and disinfecting surfaces with bleach, and patient isolation are the best ways to prevent norovirus and keep it from spreading to others,' the CDC spokesperson noted.
Outbreaks are tracked by the CDC's Vessel Sanitation Program (VSP). Recently, the the VSP was impacted by government staffing cuts at the Department of Health and Human Services, but tracking illnesses on board cruise ships continues.
Related | CDC Cuts Impacted Cruise Ship Health Inspectors—Here's What It Means for Travelers | Learn More
Read the original article on Travel & Leisure

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Miami Herald

time37 minutes ago

  • Miami Herald

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul
Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul

The Hill

time2 hours ago

  • The Hill

Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul

Former White House COVID-19 response coordinator Ashish Jha, who served under President Biden, criticized the decision by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to fire all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel. Kennedy announced the decision in an op-ed for The Wall Street Journal Monday, saying, 'A clean sweep is needed to re-establish public confidence in vaccine science.' But in an interview with CNN's Wolf Blitzer, Jha pushed back against Kennedy's reasoning. 'Look what he said in his op-ed was a series of nonsense about a group of individuals, experts…who shape what vaccines, if any, are going to be available to the American people,' Jha said in the interview. 'So obviously this is very concerning,' he continued. 'We'll have to see who he appoints next. But this is a step in the wrong direction.' Jha said he is concerned about what the move foretells about the secretary's agenda on vaccines. Jha pointed to what he characterized as a lackluster response from the secretary to 'the worst measles outbreak of the last 25 years.' He also expressed concern about Kennedy raising questions about vaccines causing autism, which Jha dismissed and said was 'settled science.' 'Then you put this in the middle of all of that,' Jha said, referring to the vaccine panel sweep, 'and what you have is a pretty clear picture that what Secretary Kennedy is trying to do is make sure that vaccines are not readily available to Americans, not just for kids, for the elderly.' 'He could go pretty far with this move, and I really am worried about where we're headed,' Jha continued. He said he's particularly concerned about the effect Kennedy's move will have on kids and whether they will continue having access to certain vaccines in the future. 'Kids rely on vaccines. I'm worried about whether the next generation of kids are going to have access to polio vaccines and measles vaccines. That's where we're heading. That's what we have to push back against.' Kennedy said in his op-ed that he was removing every member of the panel to give the Trump administration an opportunity to appoint its own members. Kennedy has long accused ACIP members of having conflicts of interest, sparking concern among vaccine advocates that he would seek to install members who are far more skeptical of approving new vaccines. But Jha pushed back against criticism that the panel was all Biden-appointed experts, saying, 'When the Biden administration came in, almost all of the appointees had come from the first Trump administration.' 'That was fine because they were good people,' he said. 'They were experts. Right now, it's the same thing. The people he is firing are experts — like a nurse in Illinois who spent her entire career getting kids vaccinated, cancer doctors from Memorial Sloan Kettering — like these are really good people.' 'And generally, CDC has not worried about when were they appointed. The question is, are they good and are they conflict free.'

Trump administration vs. mRNA vaccines
Trump administration vs. mRNA vaccines

The Hill

time2 hours ago

  • The Hill

Trump administration vs. mRNA vaccines

The Big Story President Trump once heralded the speedy development of an mRNA vaccine, but his new administration is casting doubts and fostering speculation over their use. © AP The Department of Health and Human Services (HHS) in late May canceled $766 million awarded to Moderna through the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential mRNA vaccine for bird flu. This came soon after HHS Secretary Robert F. Kennedy Jr. announced COVID-19 mRNA vaccines would no longer be recommended for children and pregnant women, though the Centers for Disease Control and Prevention (CDC) kept the shot on its schedule of childhood vaccinations. The vaccines marked a breakthrough in medical technology, drastically reducing the timeline for development of targeted vaccines and even showing promise in cancer research. Trump called mRNA the 'gold standard' when he rolled out the first COVID-19 vaccines. In remarks in December 2020, the same month the first COVID-19 vaccines were deployed, Trump praised Operation Warp Speed's ability to develop a SARS-CoV-2 vaccine at a 'breakneck speed,' adding, 'the gold standard vaccine has been done in less than nine months.' According to Joseph Varon, president and chief medical officer of the Independent Medical Alliance, the concerns for mRNA vaccine skeptics are the expedited timeline and the conditions in which the COVID-19 vaccine was approved. 'The biggest concern is that this rushed treatment still remains in use, even under an Emergency Use Authorization in some cases. It needs to be sent back through proper studies and vetting,' Varon told The Hill. In a move that could prevent future mRNA vaccines from receiving approval, Kennedy on Tuesday announced he was removing every member of the independent panel advising the CDC on vaccines. In a Wall Street Journal op-ed, he wrote, 'A clean sweep is needed to re-establish public confidence in vaccine science.' Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: Senators grill NIH director in budget hearing: 4 takeaways National Institutes of Health Director Jay Bhattacharya faced questions from senators during an Appropriations subcommittee hearing Tuesday, as the federal government agency has taken hits to its staffing levels and grant-making ability since under President Trump. Senators focused on the Trump administration's requested 2026 budget, which calls for cutting NIH's funding by $18 billion from 2025 levels. … States sue 23andMe over genetic data sales More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to auction off personal genetic information without their customers' knowledge or consent. 'The Pitt' actor Noah Wyle to make push for health care workers at Capitol Noah Wyle is heading to the pit of political power, with a visit to Capitol Hill to push for funding for programs aimed at improving mental health services for health care workers. 'The Pitt' and former 'ER' star will touch down in Washington on Thursday to lead a panel discussion at the Cannon House Office Building focused on the 'daily mental health, financial, and bureaucratic challenges for … In Other News Branch out with a different read: Collins calls Kennedy's firing of vaccine experts 'excessive' Sen. Susan Collins (R-Maine) on Monday called Health and Human Services Secretary Robert F. Kennedy Jr.'s firing of all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel 'excessive,' but she cautioned she needs to learn more about the decision. Kennedy announced the decision in an op-ed for The Wall Street Journal, catching many GOP lawmakers by surprise. 'I did not know that that had happened,' … Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: Judge declines to block Trump's Corporation for Public Broadcasting firings but allows board members to stay Correction: A previous version of this article gave incorrect names of the fired CPB board members. They are Laura Ross, Diane Kaplan and Thomas Rothman. … Read more Newsom asks judge for emergency intervention in Trump troop deployment in LA California Gov. Gavin Newsom (D) asked a federal judge to immediately intervene on Tuesday to limit President Trump's deployment of the National … Read more You're all caught up. See you tomorrow! Thank you for signing up! Subscribe to more newsletters here

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store